Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Gold and Silver Prices Dip as Markets Await Key U.S. Economic Data 
Asian Technology and Chipmaking Stocks Slide as AI Spending Concerns Shake Markets 
Wall Street Futures Slip as Tech Stocks Struggle Ahead of Key US Economic Data 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Australian Consumer Sentiment Slumps in Early December as Inflation Fears Resurface 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Oil Prices Slip in Asia as 2026 Supply Glut Fears and Russia-Ukraine Talks Weigh on Markets 
RBA Unlikely to Cut Interest Rates in 2026 as Inflation Pressures Persist, Says Westpac 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.
